Linda Grais

Linda Grais, MD, JD has broad experience in the healthcare field as a physician, entrepreneur, biopharma CEO and board member. Dr. Grais was President, Chief Executive Officer and member of the Board of Directors of Ocera Therapeutics from 2012 until its acquisition in 2017. Previously, she was a Partner at InterWest Partners, and a founder and executive vice president of Structural GenomiX, which was acquired by Eli Lilly. Dr. Grais trained in Internal Medicine and Critical Care Medicine at the University of California, San Francisco, where she was an Assistant Clinical Professor. Dr. Grais is currently a Lecturer in Management at the Stanford Graduate School of Business and a board director of several companies developing new therapeutics, including ICON plc, Arca Biopharma, and Corvus Pharmaceuticals.